期刊文献+

干扰素α-1b、白介素-2联合沙利度胺方案治疗急性髓系白血病免疫调节作用的协同机制研究 被引量:6

Synergistic Mechanism of Interferon alpha-1b,Interleukin-2 and Thalidomide for Immune Regulation in Patients with Acute Myeloid Leukemia
下载PDF
导出
摘要 目的:探讨干扰素α-1b、白介素-2联合沙利度胺(简称"干白沙"方案)治疗急性髓系白血病(AML)的免疫调节的协同作用机制。方法:对2016年3月至2019年5月郑州大学附属肿瘤医院等11家医疗单位收治的初治或复发/难治性或行维持治疗的且自愿接受"干白沙"方案治疗的68例AML患者,采集患者用药前1天及规范用药3个月后的晨起空腹外周血标本,采用流式细胞术检测外周血淋巴细胞亚群及NK细胞颗粒酶B及穿孔素表达水平;微量样本多重定量技术(CBA)检测血浆中VEGF、IFN-γ、TNF-α、IL-6等4种细胞因子的表达水平。对照组为35例本院体检中心的健康体检者。结果:治疗前患者外周血CD4+/CD8+、NK细胞比例、NK细胞穿孔素及颗粒酶B的表达水平均较健康对照者低,外周血血浆中VEGF、IL-6及TNF-α水平较健康对照组高,差异有统计学意义;IFN-γ水平较健康对照组低,但差异无统计学意义。"干白沙"方案治疗3个月后,患者外周血CD4+/CD8+比例、NK细胞比例、NK细胞穿孔素及颗粒酶B的表达水平均较用药前升高,外周血血浆中IFN-γ水平较治疗前升高,VEGF水平较治疗前降低,差异均具有统计学意义;外周血CD3+CD4+及CD3+CD8+淋巴细胞比例及血浆中TNF-α水平较治疗前升高,IL-6水平较治疗前降低,差异无统计学意义。结论:"干白沙"方案可提高外周血CD4+/CD8+比例及NK细胞比例,增加NK细胞颗粒酶B及穿孔素的表达,促进IFN-γ的产生并减少VEGF的分泌,这可能增强AML患者机体抗肿瘤能力。 Objective:To explore the synergistic immunomodulatory mechanism of interferon alpha-1b,interleukin-2 and thalidomide(ITI)regimen on patients with acute myeloid leukemia(AML).Methods:Sixty eight untreated de novo or relapsed or refractory or maintenance therapy patients with AML admitted in the Affiliated Cancer Hospital of Zhengzhou University and the other 11 medical units from March 2016 to May 2019 were treated with ITI regimen.Peripheral blood specimen per patient was collected into EDTA-K3 anticoagulation vacuum tube before the administration of ITI and 3 months after the treatment;peripheral blood lymphocyte subsets and perforin and Granzyme B expression were analyzed by using flow cytometry;the levels of VEGF,IFN-γ,TNF-αand IL-6 in the plasma were detected by using a cytometric bead array.Thirty-five healthy subjects from the hospital physical examination centre were selected as normal controls.Results:The ratio of CD4^+/CD8^+T cells,the percentage of NK cells,the expression of perforin and Granzyme B of NK cells in the peripheral blood of patients with hematological malignancies were lower than those of healthy controls.The level of VEGF,IL-6 and TNF-αin the peripheral plasma were higher than those of the healthy control group,and the difference was statistically significant.The level of IFN-γwas lower,and the difference was not statistically significant.The ratio of CD4^+/CD8^+T cells,the percentage of NK cells,the expression of Granzyme B and Perforin of NK cells in peripheral blood were higher after the therapy of thalidomide combined with rhIFNα-1b for 3 months as compared with those before treatment of ITI,the level of the IFN-γin peripheral plasma was higher while that of VEGF was lower,the difference was statistically significant;after treatment,the ratio of CD3^+CD4^+and CD3^+CD8^+lymphocytes and the level of TNF-αin peripheral blood were higher those that before treatment,IL-6 was lower,while the difference was not statistically significant.Conclusion:The ITI regimen can raise the ratio of CD4^+/CD8^+T cells and the percentage of natural killer cells,also,can enhance the generation of perforin and granzyme B and the concentration of IFN-γas well as inhibit the generation of VEGF,suggesting that these activities may enhance the antitumour capacity of patients with AML.
作者 米瑞华 陈琳 周亚兰 李冬贝 刘莎 汪小姣 刘佳 王敏芳 马晓苗 李志春 赵红勉 徐禹林 陈淑霞 杨海平 郭志强 栾春来 郭淑利 宋庆林 魏旭东 MI Rui-Hua;CHEN Lin;ZHOU Ya-Lan;LI Dong-Bei;LIU Sha;WANG Xiao-Jiao;LIU Jia;WANG Min-Fang;MA Xiao-Miao;LI Zhi-Chun;ZHAO Hong-Mian;XU Yu-Lin;CHEN Shu-Xia;YANG Hai-Ping;GUO Zhi-Qiang;LUAN Chun-Lai;GUO Shu-Li;SONG Qing-Lin;WEI Xu-Dong(Cancer Hospital Affiliated to Zhengzhou University/Henan Cancer Hospital,Zhengzhou 450008,Henan Province,China;Pingdingshan First People's Hospital,Pingdingshan 467000,Henan Province,China;Puyang City People's Hospital,Puyang 457000,Henan Province,China;Huaihe Hospital of Henan University,Kaifeng 475000,Henan Province,China;th,Hospital of PLA,Luoyang 471000,Henan Province,China;Shangqiu city First People's Hospital,Shangqiu 476000,Henan Province,China;First Affiliated Hospital of Science and Technology University of Henan,Luoyang 471000,Henan Province,China;Central Hospital of Zhengzhou,Zhengzhou 450000,Henan Province,China;Anyang District Hospital,Anyang 455000,Henan Province,China;Central Hospital of Luoyang,Luoyang 471000,Henan Province,China;nJiaozuo People's Hospital,Jiaozuo 454150,Henan Province,China)
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2021年第1期26-31,共6页 Journal of Experimental Hematology
基金 河南省医学科技攻关计划省部共建项目(201701027)。
关键词 髓系白血病 干扰素 白介素-2 沙利度胺 免疫调节 myeloid leukemia interferon interleukin-2 thalidomide immune regulation
  • 相关文献

参考文献3

二级参考文献17

  • 1申加英,杨萍,刘志梅.干扰素α对U937细胞的诱导凋亡及其作用机制探讨[J].临床血液学杂志,2005,18(1):37-39. 被引量:6
  • 2孙立荣,于宏,庞秀英,李学荣,卢愿,宋爱琴,仲任,赵艳霞.干扰素α-2b对人类早幼粒白血病细胞株HL-60细胞的抑制增殖与促进凋亡的作用(英文)[J].中国组织工程研究与临床康复,2007,11(50):10217-10220. 被引量:1
  • 3Steins MB, Padr6 T, Bieker R, et al. Efficacy and safety of thalid- omide in patients with acute myeloid leukemia[J]. Blood, 2002, 99(3): 834-839.
  • 4Hill NO, Pardue A, Khan A, et al. Clinical trials of human leuko- cyte interferon in malignancy [J]. Tex Rep Biol Med, 1981/ 1982, 41: 634-640.
  • 5Arellano ML, Langston A, Winton E, et al. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience [J]. Biol Blood Marrow Transplant, 2007, 13 (1): 116-123.
  • 6McSweeney EN, Worman CP, Tsakona CP, et al. Low-dose recombinant alfa-2a-interferon: a feasible maintenance therapy in acute myeloid leukaemia in the older patient [J]. ActaHaematol, 1993, 89( 1 ): 1-5.
  • 7Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis [J]. Oncogene, 2003, 22 (53): 8590- 8607.
  • 8Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bel- 2 family members [J]. Biochim Biophys Acta, 2004, 1644(2/3): 107-113.
  • 9Cryns V, Yuan J. Protease to die for[J]. Genes Dev, 1998, 12 (11): 1551-1570.
  • 10Mayer IA, Verma A, Grumbach IM, et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon- alpha in BCR-ABL-expressing cells [ J ]. J Biol Chem, 2001,276 (30): 28570-28577.

共引文献25

同被引文献51

引证文献6

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部